➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Boehringer Ingelheim
Express Scripts
Johnson and Johnson
AstraZeneca

Last Updated: May 30, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Serlopitant


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Serlopitant?

Serlopitant is an investigational drug.

There have been 12 clinical trials for Serlopitant. The most recent clinical trial was a Phase 2 trial, which was initiated on March 15th 2018.

The most common disease conditions in clinical trials are Pruritus, Prurigo, and Neurodermatitis. The leading clinical trial sponsors are Menlo Therapeutics Inc., Epidermolysis Bullosa Research Partnership, and Stanford University.

There are sixteen US patents protecting this investigational drug and seventy international patents.

Recent Clinical Trials for Serlopitant
TitleSponsorPhase
A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis BullosaEpidermolysis Bullosa Research PartnershipPhase 2
A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis BullosaMenlo TherapeuticsPhase 2
A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis BullosaStanford UniversityPhase 2

See all Serlopitant clinical trials

Clinical Trial Summary for Serlopitant

Top disease conditions for Serlopitant
Top clinical trial sponsors for Serlopitant

See all Serlopitant clinical trials

US Patents for Serlopitant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Serlopitant   Start Trial   Start Trial
Serlopitant   Start Trial Use of NK-1 receptor antagonist serlopitant in pruritus Menlo Therapeutics Inc. (Redwood, CA)   Start Trial
Serlopitant   Start Trial Hydroisoindoline tachykinin receptor antagonists Merck & Co., Inc. (Rahway, NJ)   Start Trial
Serlopitant   Start Trial Hydroisoindoline tachykinin receptor antagonists Merck & Co., Inc. (Rahway, NJ)   Start Trial
Serlopitant   Start Trial Process for making hydroisoindoline tachykinin receptor antagonists Merck & Co, Inc. (Rahway, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Serlopitant

Drugname Country Document Number Estimated Expiration Related US Patent
Serlopitant Australia 2014302694 2033-06-24   Start Trial
Serlopitant Brazil 112015031724 2033-06-24   Start Trial
Serlopitant Canada 2915474 2033-06-24   Start Trial
Serlopitant China 105473138 2033-06-24   Start Trial
Serlopitant European Patent Office 3013336 2033-06-24   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Baxter
Harvard Business School
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.